Studies that have used an unbiased approach to stratify 1079 MDS patients using mutational and morphological profiles have indicated that STAG2 mutations are related to the morphological category of myeloid dysplasia, elevated megakaryocytes and constituted an adverse risk group (Nagata et al., 2020). Here, STAG2 is linked to myelodysplastic syndrome.